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SUMMARY 
 
Objective 
 
To test the hypothesis that angiogenesis in prostate cancer is associated with tumour 
invasion and metastasis, and that this is mediated via increased COX-2 expression. 
Materials and Methods 
We studied angiogenesis in 105 patients with either prostate cancer (79) or BPH (26). 
We correlated this data with levels of COX-2 expression in the same dataset. Mean 
microvessel density was analysed, as a marker of angiogenesis, using the endothelial 
antigen CD34 stained by immunohistochemistry.  
Results 
There was no difference in MVD in progressive tumour stages compared to BPH. 
There was a negative correlation between MVD and COX-2 expression, however the 
effect of increased COX-2 expression on MVD was not marked.  
Conclusion 
This data would suggest that COX-2 drives tumour spread in prostate cancer by means 
other than the promotion of angiogenesis. 
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INTRODUCTION 
Angiogenesis, the formation of new blood vessels, plays a vital role in the growth, 
progression and metastasis of many cancers [1]. Solid tumours induce the formation of 
new capillaries to avoid oxygen starvation and obtain the required nutrients to grow 
beyond 2-3mm in diameter [1]. The regulation of angiogenesis depends on a complex 
interplay between pro-angiogenic factors such as vascular endothelial growth factors 
(VEGFs) and inhibitory factors, known as the “angiogenic switch” [1,2]. 
Immunohistochemical (IHC) studies for endothelial antigens such as von Willebrands 
factor (Factor VIII), CD 31 and CD 34 are frequently used to quantify 
neovascularisation in tumours. Such studies have suggested that estimation of mean 
microvessel density (MVD) predicts local spread and recurrence in several cancers 
[1,3,4]. In addition, studies have suggested that angiogenesis contributes to the 
metastatic potential of prostate cancer [1,5] The administration of angiogenesis 
inhibitors has been shown to suppress the primary and metastatic growth of prostate 
tumours in vivo [1].  A number of retrospective studies have shown mean MVD to 
correlate with increasing Gleason score and disease progression (from extraprostatic 
extension to metastasis) in prostate cancer [4,5,5]. However, the clinical value of 
measuring angiogenesis remains controversial. Estimation of mean MVD has not 
always been shown to predict local recurrence, nor relate to Gleason score or stage [6]. 
In addition, some studies have been unable to confirm that MVD can act as an 
independent prognostic parameter for prostate cancer when subjected to multivariate 
analysis [1,7] 
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COX-2 is the inducible form of the enzyme cyclo-oxygenase, which is involved in the 
formation of prostaglandins such as PGE2 from arachidonic acid, which in turn 
regulates VEGF production, thereby promoting angiogenesis [8]. Aberrant or increased 
expression of COX-2 has been implicated in the pathogenesis of several human cancers 
including colorectal [9] , and breast [10,11]. A recent report revealed a correlation 
between COX-2 expression and tumour MVD as measured by CD31 in breast cancer 
[11]. This provides the rationale for the use of selective COX-2 inhibitors in the 
treatment of selected cancer patients, in order to reduce neovascularisation and 
therefore cell growth, which is currently under investigation [1]. 
 
Increased expression of COX-2 has already been shown in the prostate cancer cell lines 
LNCaP (androgen sensitive), and PC-3 (androgen insensitive) [12] [10]. 
Immunohistochemical studies, including our own, have confirmed high levels of COX-
2 expression in human prostatic cancer tissue and high grade PIN [13-17]. Correlation 
between COX-2 staining intensity, Gleason score, and poor prognosis in prostate 
cancer has been shown in some studies [16-18].  but not others [13]. We have recently 
demonstrated higher levels of COX-2 expression in locally advanced prostate cancer 
[19].  Studies in hormone-resistant prostate cancer cell lines have demonstrated a link 
between COX-2, PGE2 production and the hypoxic upregulation of VEGF, which may 
be reversed by the addition of a selective COX-2 inhibitor [20]. Similarly, prostate 
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cancer studies in mice demonstrate that treatment with selective COX-2 inhibitors 
prevents the up-regulation of VEGF decreasing tumour MVD and tumour growth [21]. 
We tested the hypothesis that angiogenesis in prostate cancer is associated with tumour 
invasion and metastasis and mediated via increased COX-2 expression. The 
confirmation of angiogenesis and COX-2 as consistent prognostic markers in prostate 
cancer would support further clinical assessment of angiogenesis and COX-2 
inhibitors, which have already shown promise in various trials [1,22].   
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MATERIALS AND METHODS 
  
Patient Recruitment and Tissue Retrieval 
A database of 105 tumour biopsies was established with archival tissue specimens 
(formalin fixed, paraffin embedded). Detailed data on stage, presence of metastasis, 
Gleason grade and survival data if available was documented upon review of case 
notes. In order to develop this patient cohort, we obtained Multiple Research Ethical 
Committee approval and the support of the Scottish Urological Oncology Group and 
recruited patients throughout Scotland. Tissue specimens were then divided into 2 
groups by stage (T1/2 and T3/4) with BPH specimens as control. Two further 
subgroups with non-metastatic and metastatic disease at presentation were also 
identified.  COX-2 expression data was also available for each tumour in this cohort. 
[19].  
 
Methods 
Tumour angiogenesis was assessed by immunohistochemistry (IHC) using a 
monoclonal antibody to the endothelial cell surface marker CD34 (mouse IgG1, 
QBEnd/10, Novocastra, UK). Tissue sections (5µm) were dewaxed in xylene and 
rehydrated through graded alcohols. Antigen retrieval was achieved by incubating 
sections in 0.1% trypsin in 0.1% calcium chloride (w/v, pH4) for 25 minutes at 370C. 
Sections were then incubated with primary antibody at 1:50 dilution for 30 minutes at 
room temperature. Negative control sections were incubated with an isotype matched 
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control antibody. Bound antibody was visualised using a biotinylated secondary 
antibody, streptavidin-horseradish peroxidase complex (DAKO, UK) and 3,3’-
diaminobenzidine (DAB) as chromogen (Vector). Tissue sections were counterstained 
with haematoxylin and dehydrated through graded alcohols and xylene. Subjective 
analysis of the tissue sections was used to identify 4 most vascular regions or “hot 
spots” (areas of maximal endothelial cell staining of microvessels) at low 
magnification (x 200). The number of vessels in each hot spot was then counted at 
higher magnification (x 400) in four fields of vision – the average of these counts was 
taken as the mean microvessel density (MVD). Every tenth slide was double-scored by 
an independent observer. 
 
COX-2 expression was previously determined using a monoclonal antibody (mouse 
IgG1, Cat.No.160112, Cayman Chemical Co., USA) at a 1:80 concentration. This was 
quantified blindly by the same 2 observers using a weighted histoscore method, which 
is calculated from the sum of (1 x % weak staining) + (2 x % moderate staining) + (3 x 
% strong staining) and provides a semi-quantitative classification of staining intensity.  
The inter-class correlation coefficients (ICCC) between each observer for each protein 
were greater than 0.7, which is classed as excellent.   
 
 
Data Analysis 
MVD scores are shown as mean +/- standard deviation. Statistical analysis was 
performed using the student’s T-test to compare differences in scores between BPH 
 8 
and individual tumour stages. Spearman ranks correlation coefficient was used to 
determine any correlation between COX-2 expression, angiogenesis (as determined by 
mean MVD), and Gleason score. Kaplan-Meier survival plots were used to correlate 
MVD scores with survival. 
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RESULTS 
 
Angiogenesis  
In total, 105 patients were retrospectively recruited into the study, 79 had prostate 
cancer (46 with stage T1/2 and 31 with stage T3/4, and 2 stage unknown) and 26 had 
BPH (see Figure 1). Tumour groups were also subdivided into metastatic (11 T1/2, 7 
T3/4, 2 unknown) and non-metastatic (35 T1/2, 24 T3/4) at presentation. Median age, 
Gleason sum and mean survival for all patients in the database are shown in Table 1. 
There was no difference in angiogenesis, as measured by MVD, between tumour 
groups (all groups combined) compared to BPH (p=0.19), nor with T3/4 compared 
with T1/2 (p=0.95) (see Table 2a) when the data was subjected to the student’s T-test. 
In addition, no significant differences were seen between patients with or without 
metastasis at diagnosis either in total (p=0.60) (see Table 2a), or when further sub-
divided by individual tumour stage (p=0.39 for T1/2 and p=0.96 for T3/4) (see Table 
2b). Patients with high MVD (above mean) did not show a significantly different 
survival time compared to patients with low MVD (below mean) (p=0.15). 
 
Correlation between COX-2 and angiogenesis 
There was a negative correlation between COX-2 expression and angiogenesis, as 
measured by micro-vessel density, (p=0.02, y = -0.027x + 18.58) (see Table 3 and 
Figure 2). In addition, Gleason score did not correlate with MVD nor COX-2 
expression (p=0.75 and 0.40 respectively). 
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DISCUSSION 
 
We have previously published an association between high COX-2 expression and 
increased tumour stage (T3/4), and increased COX-2 expression in prostate cancer 
compared with BPH [19].   This confirms previous studies in which COX-2 expression 
is associated with aggressive disease in prostate cancer [16-18] and led to the 
hypothesis that COX-2 drives increased neovascularisation. In support of this, a recent 
study in breast cancer demonstrated a positive relationship between COX-2 expression 
(as measured by weighted histoscore) and angiogenesis as measured by mean MVD 
using the CD31 antigen [11]. Interestingly our results demonstrated a significant 
negative correlation between angiogenesis, as measured by CD34 expression, and 
COX-2 expression. This would contradict the hypothesis that COX-2 acts as a pro-
angiogenic stimulant at least in prostate cancer, and could suggest that COX-2 inhibits 
new blood vessel formation. However, the drop in MVD associated with a rise in 
COX-2 expression was lower than the observed variation in MVD at individual COX-2 
expression levels (see Figure.2). For example, a rise in COX-2 expression from 100 to 
300 histoscore units would result in a theoretical reduction in MVD from 15.88 to 
10.48 microvessels/field (a fall of 5.4 units). However the actual mean MVD observed 
between COX-2 histoscores of 140-160, for example, is 17.76 +/- 9.9 (standard 
deviation) microvessels/field. At this point the variation in MVD scores is almost twice 
the maximum change predicted (since 90% of samples have a COX-2 histoscore 
between 100-300). This suggests that the variation in measurement of MVD would 
preclude its use as a prognostic or predictive factor. Furthermore, the high variation in 
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MVD scores at individual COX-2 scores would, in our view, undermine the biological 
significance of the observed negative correlation between MVD and COX-2 
expression. It is tempting to speculate that if a sub analysis could be performed 
comparing mean MVD in focal areas of high or low COX-2 expression alone, then less 
variation been may have been encountered. In practice, however, this would not be 
technically feasible due to the diffuse and heterogeneous nature of COX-2 staining 
within individual tissue sections. In addition there are inherent difficulties in 
accurately comparing protein expression within specific areas between different tissue 
sections, in the absence of a dual staining technique. The weighted histoscore 
technique for measuring COX-2 expression is therefore well established and has been 
used previously in comparison with mean MVD scores in breast tissue [11,16-19]. 
 
Whilst our results therefore may reflect the methodological problems associated with 
MVD measurement, it may also imply that COX-2 drives tumour progression 
independently of neovascularisation. For example, COX-2 has well documented roles 
in the promotion of the inflammatory response, inhibition of apoptosis via the Akt/bcl-
2 pathway, and is involved in the control of cellular proliferation via the IL-6 pathway 
[23].  Studies in breast cancer have revealed cellular proliferation, as measured by 
mitotic activity index (MAI), to have no association with angiogenesis as measured by 
MVD [3].  
 
The importance of angiogenesis in tumour metastasis has been well established for 
over 30 years [1]. In theory inhibition of angiogenesis may provide a further 
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therapeutic option by targeting cancer growth and spread. In our own study however, 
angiogenesis, as measured by mean microvessel density in prostate cancer, was not 
seen to increase with increasing tumour stage or metastases in line with some studies 
[6,7].  However other studies have been able to demonstrate a relationship between 
mean MVD and advancing disease in prostate cancer [4,5,24,25]. There are similar 
inconsistencies with the use of MVD determination as a prognostic indicator in 
colorectal cancer, where MVD was lower in metastatic than primary tumours [26], and 
to a lesser extent in breast cancer [27]. These differences may be related to the use of 
different antibodies, as our MVD scores were lower than previously published results 
using Factor VIII and CD31 as an endothelial antigen [5,6,25]. This has also been 
reported in breast cancer when CD31 was compared to Factor VIII [6].  However 
disparities between MVD scores have also been reported between studies using the 
same antibody [4,6]. Furthermore, a recent report associating MVD with outcome after 
radical prostatectomy, quoted scores of a similar magnitude to ours when using CD34 
as a antigen [28]. Similar scores to our study were also found when our protocol of 
MVD determination using CD34 was incorporated into a pilot study of breast cancer 
specimens within our laboratory (results unpublished). Other well-documented 
controversies do exist in angiogenesis determination, such as the presence of tumour 
heterogeneity [1,7]. Other aspects of methodology, such as the actual region selected 
for vessel counting may be as important [1,6].  If angiogenesis measurement alone is to 
be exploited for clinical use, current methods involving MVD analysis need to be 
simplified and standardised [1]. Further prospective studies are needed to explore its 
potential as a prognostic marker in prostate cancer. However, despite the possible 
 13
inverse correlation between mean MVD and COX-2 expression in our study, this study 
does not preclude the targeting of angiogenesis as a treatment modality. Angiogenesis 
is regulated by a complex series of molecular pathways, which, whilst they include the 
modulation of VEGF via PGE2 produced by COX-2, are subject to many other 
modulatory factors. We would therefore conclude that it is unrealistic to correlate 
COX-2 with a distant end-point such as angiogenesis. A more appropriate relationship 
may be found if VEGF expression itself was determined.  
 
In summary, tumour angiogenesis, as measured by MVD determination using an 
antibody to CD34, does not increase with tumour stage. It also appears to have a weak 
negative relationship with the expression of the pro-angiogenic factor COX-2 in our 
study.  This study raises the possibility that COX-2 may influence tumour progression 
in prostate cancer through mechanisms other than the promotion of angiogenesis. The 
use of selective COX-2 and angiogenesis inhibitors may still have a role in the targeted 
treatment of prostate cancer in the future and indeed this study might suggest these 
agents could be used in combination. 
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